Results 11 to 20 of about 1,341,600 (296)

The "Climb" Towards Minimal Disease Activity in Psoriatic Arthritis. [PDF]

Rheumatol Ther, 2021
Minimal disease activity (MDA) is a validated outcome measure in psoriatic arthritis (PsA) defining a low disease activity state with a cutoff of 5/7. The main aim of the study was to look at the MDA divided into in the seven cutoffs, analyzing the more frequently achieved domains.
Lubrano E, Scriffignano S, Perrotta FM.
europepmc   +5 more sources

On Modelling Minimal Disease Activity. [PDF]

Arthritis Care Res (Hoboken), 2016
ObjectiveTo explore methods for statistical modelling of minimal disease activity (MDA) based on data from intermittent clinic visits.MethodsThe analysis was based on a 2‐state model. Comparisons were made between analyses based on “complete case” data from visits at which MDA status was known, and the use of hidden model methodology that incorporated ...
Jackson CH, Su L, Gladman DD, Farewell VT.   +3 more
europepmc   +5 more sources

Measurement properties of the minimal disease activity criteria for psoriatic arthritis. [PDF]

RMD Open, 2019
Objective To comprehensively assess evidence on the measurement properties of the minimal disease activity (MDA) criteria, a composite measure of the state of disease activity in psoriatic arthritis (PsA). Methods A targeted literature review was ...
Coates LC, Strand V, Wilson H, Revicki D, Stolshek B, Samad A, Chung JB, Gladman D, Mease PJ.   +8 more
europepmc   +5 more sources

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis. [PDF]

Arthritis Care Res (Hoboken), 2018
ObjectiveTreat‐to‐target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target minimal disease activity (MDA) and the articular target Disease Activity index for PsA (DAPSA).
Wervers K, Vis M, Tchetveriko I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Luime JJ.   +11 more
europepmc   +6 more sources

Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study [PDF]

Терапевтический архив, 2018
Objectives: to study efficacy of treat-to-target (T2T) strategy in early peripheral psoriatic arthritis (EPsA) after one year of treatment. Methods: 44 (M/F - 18/26) DMARD-naїve patients (pts) with active EPsA, according to the CASPAR criteria, mean age ...
T V Korotaeva, E Yu Loginova, T S Getiya, E L Nasonov   +3 more
doaj   +1 more source

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry

Современная ревматология, 2021
The goal of psoriatic arthritis (PsA) therapy is to achieve remission or minimal disease activity (MDA). According to the EULAR guidelines, synthetic disease-modifying antirheumatic drugs (sDMARDs), methotrexate (MTX) in particular, are first-line ...
T. V. Korotaeva, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavsky, I. N. Kushnir, I. F. Umnova, S. S. Kudishina   +8 more
doaj   +1 more source

Aberrant Polycystin-1 Expression Results in Modification of Activator Protein-1 Activity, whereas Wnt Signaling Remains Unaffected [PDF]

, 2004
Polycystin-1, the polycystic kidney disease 1 gene product, has been implicated in several signaling complexes that are known to regulate essential cellular functions. We investigated the role of polycystin-1 in Wnt signaling and activator protein-1 (
Arnould, Bhunia, Duyndam, Giles, Grotewold, Huan, Kim, Kimberling, Kugoh, Loghman-Adham, Löhning, Morin, Moser, Muto, Newby, Ouwens, Parnell, Peters, Pritchard, Rivat, Rodova, Saadi-Kheddouci, Scheffers, Shaulian, Smits, Sorenson, Spaargaren, Streets, Sutters, Trudel, Upadhya, van Adelsberg, van Dam, van Dam, van Dam, van Dam, van de Wetering, van de Wetering   +37 more
core   +15 more sources

Influence of the duration of psoriatic arthritis on the achievement of remission and minimal disease activity during therapy with genetically engineered biologic drugs. Data from the all-russian register of patients with psoriatic arthritis

Научно-практическая ревматология, 2021
Aim. To study the frequency and timing of the onset of remission and minimal disease activity after the administration of genetically engineered biologic drugs (GEBD) in patients with early and long-term psoriatic arthritis observed within the framework ...
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavskiy, I. N. Kushnir, I. F. Umnova, S. S. Kudishina, E. L. Nasonov   +9 more
doaj   +1 more source

Residual disease activity in psoriatic arthritis: discordance between the rheumatologist’s opinion and minimal disease activity measurement [PDF]

Rheumatology, 2017
To assess how many PsA patients with an acceptable disease state according to the treating rheumatologist have quiescent disease defined as minimal disease activity (MDA).This cross-sectional study included 250 PsA patients. To assess current clinical practice as closely as possible, acceptable disease state was not determined by predefined activity ...
van Mens, Leonieke J J, Turina, Maureen C, van de Sande, Marleen G H, Nurmohamed, Mike T, van Kuijk, Arno W R, Baeten, Dominique L P   +5 more
openaire   +3 more sources

Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Rheumatology and Therapy, 2022
Plain Language Summary Psoriatic disease is a group of heterogeneous inflammatory conditions, mainly affecting patients’ skin and joints. Among the few biomarkers associated with inflammation in psoriatic disease, serum calprotectin may be a promising ...
Borui Li, Guangtao Li, Zhibo Song, Zhuoli Zhang   +3 more
doaj   +1 more source